MTIP
IRMD icon

Magee Thomson Investment Partners’s iRadimed IRMD Stock Holding History

Magee Thomson Investment Partners’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-118
Closed -$2K – 101
2016
Q1 		$2K Hold
118
– – ﹤0.01% 96
2015
Q4 		$4K Sell
118
-156
-57% -$4.41K ﹤0.01% 80
2015
Q3 		$7K Buy
274
+2
+0.7% +$48 ﹤0.01% 38
2015
Q2 		$6K Buy
+272
New +$4.97K ﹤0.01% 48

Other funds holding IRMD

CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MCM
McKinley Capital Management Anchorage, Alaska $571M AUM 36.44% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
TCM
Timpani Capital Management Milwaukee, Wisconsin $209M AUM 62.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Magee Thomson Investment Partners's IRMD Position: Q2 2016 in Review

Magee Thomson Investment Partners sold out of iRadimed (IRMD) in Q2 2016, closing a stake of 118 shares — an estimated $2K sold.

Magee Thomson Investment Partners first reported a position in IRMD in Q2 2015 and held it in 4 quarters. The position peaked at $7K in Q3 2015. 60 funds tracked by Wall St. Rank hold IRMD as of Q2 2016.

  • Magee Thomson Investment Partners reported no remaining iRadimed position as of Q2 2016 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 118 iRadimed shares in Q2 2016, an estimated $2K.
  • Magee Thomson Investment Partners first reported a position in iRadimed in Q2 2015 and held it in 4 quarters.
  • Magee Thomson Investment Partners's iRadimed position peaked at $7K in Q3 2015.
  • 60 funds tracked by Wall St. Rank held iRadimed as of Q2 2016.

Based on Magee Thomson Investment Partners's 13F filing for Q2 2016, filed 21 Jul 2016.